Sofregen Medical

Executive Summary

Sofregen Medical is a privately held regenerative medicine company headquartered in Medford, Massachusetts, that leverages proprietary silk fibroin technology to develop natural, silk-based implants and injectables for soft tissue regeneration. Founded in 2013, the company targets aesthetic procedures and functional reconstructive surgeries, with a lead focus on vocal fold repair. By repurposing purified silk protein, Sofregen aims to overcome limitations of synthetic and cadaveric implants, offering a durable, biocompatible solution that integrates with native tissue. The company's platform has the potential to address significant unmet needs in laryngology and aesthetic medicine, where safe, long-lasting regenerative options are scarce. While Sofregen has not disclosed public funding details or valuation, its innovative approach and niche application in vocal fold repair position it as a differentiated player in the regenerative biomaterials space. Commercial traction and clinical data remain limited, but the underlying technology has shown promise in preclinical and early clinical settings, warranting close monitoring as the company progresses toward regulatory milestones.

Upcoming Catalysts (preview)

• H2 2026FDA 510(k) clearance or clinical trial initiation for vocal fold injection laryngoplasty55% success
• H1 2027Partnership or licensing deal with a major aesthetic/medical device company40% success
• 2026Series C financing round to support commercialization and clinical expansion60% success